



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 219 291 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
03.07.2002 Bulletin 2002/27

(51) Int Cl.7: **A61K 9/00, A61K 9/14,**
A61K 9/16, A61K 9/28

(21) Application number: 01310751.1

(22) Date of filing: 21.12.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

- **McTeigue, Daniel**
N. Wales, PA 19454 (US)
- **Wynn, David W.**
Abington, PA 19001 (US)
- **Pillai, Ravivaj S.**
Lansdale, PA 19446 (US)

(30) Priority: 21.12.2000 US 745243

(71) Applicant: **McNeill-PPC, Inc.**
Skillman, NJ 08858 (US)

(74) Representative: **Mercer, Christopher Paul et al**
Carpmaels & Ransford
43, Bloomsbury Square
London WC1A 2RA (GB)

(72) Inventors:

- **Parikh, Narendra**
Long Valley, NJ 07853 (US)

(54) **Texture masked particles containing an active ingredient**

(57) Texture masked particles and chewable tablets made therefrom are disclosed. The texture masked particles are comprised of a core containing an active ingredient, an optional first coating layer comprised of a taste masking agent that substantially covers the core; and a second coating layer, which optionally may sub-

stantially cover the first coating layer or the core, comprised of a film forming polymer and a anti-grit-agent. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient.

EP 1 219 291 A1

Description

5 [0001] This invention relates to texture masked particles containing an active ingredient and a polymeric overcoating mixture of a water soluble or water swellable film forming polymer and an anti-grit agent. The coated particles may be used to make chewable tablets or rapidly disintegrating tablets that conveniently may be administered without water.

Background of the Invention

10 [0002] Pharmaceuticals intended for oral administration are typically provided in solid form as tablets, capsules, pills, lozenges, or granules. Tablets are swallowed whole, chewed in the mouth, or dissolved in the oral cavity. Chewable tablets are typically made from a mixture including active drug particles, and other inactive ingredients (excipients), and are often employed for the administration of pharmaceuticals where it is impractical to provide a tablet for swallowing whole. With chewable tablets, the act of chewing helps to break up the tablet particles as the tablet disintegrates and may increase the rate of absorption by the digestive tract. Chewable tablets are often utilized to improve drug administration in pediatric and geriatric patients.

15 [0003] Certain drug particles have a bitter or otherwise unpleasant taste. In order to make palatable chewable tablets from these, their taste must be masked for example by dispersing or coating the particles with a coating composition as disclosed in, for example, United States Patent Numbers 4,851,226; 5,489,436; 5,529,783; 5,215,755; 5,260,072; 5,460,825; 4,800,087; 5,814,332; and 5,075,114, which are incorporated by reference herein. In general, such efforts have focused on masking the unpleasant taste of the drug by coating the drug particles with, polymers designed to delay dissolution until the drug has cleared the oral cavity. However, after the other ingredients in the tablet matrix dissolve away, the coated drug particles are often left in the mouth with their gritty, sandy texture. This is particularly of concern with rapidly disintegrating dosage forms that are becoming more popular.

20 [0004] Various attempts have been made to enhance the texture of drug particles in order to prevent their adhesion to the oral mucosa upon ingestion. For example, WO88/06893 discloses an oral composition comprised of an active substance and a gelling or swelling agent capable of forming a viscous medium around the particles in an aqueous carrier. Disadvantageously, such compositions must be disintegrated in water to form a liquid suspension before ingestion for purposes of facilitating the ease of quickly swallowing the composition without chewing.

25 [0005] It would be desirable to have an oral dosage form that effectively masks the texture or both the taste and the texture of active materials, such as drug particles, during ingestion, which thereby obviates the need for consumption with water; and that also may be chewed.

Summary of the Invention

35 [0006] The present invention provides a texture masked particle comprising, consisting of, or consisting essentially of:

- a) a core containing an active ingredient;
- b) a first coating layer comprised of a taste masking agent that substantially covers the core; and
- 40 c) a second coating layer on the surface of the first coating layer, the second coating layer comprised of, consisting of, or consisting essentially of:

- i) a film forming polymer; and
- ii) an anti-grit agent.

45 [0007] The invention also provides a texture masked particle comprising, consisting of, or consisting essentially of:

- a) a core containing an active ingredient; and
- b) a texture masking coating layer on the surface of the core, the texture masking coating layer comprised of, consisting of, or consisting essentially of

- 50 i) a film forming polymer; and
- ii) an anti-grit agent.

55 [0008] The invention further provides a method of texture masking particles comprising an active ingredient, which comprises, consists of, or consists essentially of:

- a) applying a substantially continuous first coating layer over the particles, the first coating layer comprising a taste masking agent; and

b) applying a second coating layer over the first coating layer, the second coating layer comprising, consisting of, or consisting essentially of a mixture of a) a film forming polymer; and b) an anti-grit agent.

[0009] The invention further provides a method of texture masking particles comprising an active ingredient, which comprises, consists of or consists essentially of:

applying a coating layer on the surface of a core comprising the active ingredient, the coating layer comprising, consisting of, or consisting essentially of a mixture of a) a film forming polymer; and b) an anti-grit agent.

[0010] The invention further provides a method of making texture masked particles comprising an active ingredient, which comprises, consists of or consists essentially of:

spray-drying a mixture comprising

- a) a film forming polymer and an anti-grit agent which are both present in an amount effective for texture masking the active ingredient; and
- b) the active ingredient.

[0011] The invention further provides a texture masked particle comprised of a matrix, the matrix comprising, consisting of, or consisting essentially of:

- a) an active ingredient,
- b) a film forming polymer, and
- c) an anti-grit agent,

wherein the film forming polymer and anti-grit agent are exposed at the surface of the particle in an amount effective for texture masking the active ingredient.

[0012] In accordance with this invention, texture masked pharmaceutical formulations having an immediate release profile may be made using an overcoating comprising a mixture of a film forming polymer and an anti-grit agent. This texture masking overcoating not only overcomes the gritty texture of the drug particles, but also facilitates ease of swallowing. Moreover, the formulations may conveniently be ingested without the need for water. The overcoated particles of the invention advantageously exhibit sufficient elasticity without the need for added plasticizers to maintain integrity during tableting and prevent release of the drug into the mouth during chewing. Chewable tablets made from these coated particles have excellent taste and yet surprisingly exhibit an immediate release profile.

Detailed Description of the Invention

[0013] As used herein, the term "substantially covers" or "substantially continuous" means that the coating is generally continuous and generally covers the entire surface of the core or underlying layer, so that little to none of the active ingredient or underlying layer is exposed.

[0014] The core of the texture masked particle may comprise any one of a number of active ingredients. Suitable active ingredients broadly include pharmaceutically active ingredients, dietary supplements, nutritionals, nutraceuticals, and the like. More specifically these include analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents, vitamins, minerals, anti-infectives, nutrients, and mixtures thereof. One class of preferred active ingredients include nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, rofecoxib, celecoxib, and aspirin. The active ingredient may alternatively be selected from acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, loperamide, ranitidine, cimetidine, bisacodyl, psyllium, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, mixtures thereof and pharmaceutically acceptable salts or metabolites thereof. Most preferably, the active ingredient is selected from the group consisting of acetaminophen, ibuprofen, pseudoephedrine, dextromethorphan, diphenhydramine, chlorpheniramine, loratadine, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium oxide, aluminum hydroxide, mixtures thereof, and pharmaceutically acceptable salts thereof.

[0015] The core of the particle may comprise pure, crystalline active ingredient, or a mixture of active ingredient with optional ingredients, such as binders, excipients and the like known in the art. The core may be formed using a variety of well known granulation methods, including high sheer wet granulation, spray drying, and fluid bed granulation (including rotary fluid bed granulation). Preferably, the particle core is made by fluid bed granulation. Preferably the average diameter of the core of the particle is from about 80 to about 300 microns.

[0016] In one embodiment, the first coating layer, which is comprised of a taste masking agent, substantially covers the core. Examples of suitable taste masking agents include, but are not limited to cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride), which is commercially available from Rohm Pharma under the tradename, "EUDRAGIT", hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and mixtures thereof.

[0017] In another embodiment, the taste masking agent is comprised of a mixture of a) an enteric polymer and b) and insoluble film forming polymer. The enteric polymer may be selected from any one of a variety of known enteric polymers, such as hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, and polymethacrylate-based polymers such as poly(methacrylic acid, methyl methacrylate) 1:2, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT S" polymers, and poly(methacrylic acid, methyl methacrylate) 1:1, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT L" polymers. Combinations of enteric polymers may also be used.

[0018] Preferably, the enteric polymer is selected from non-acrylate compounds, specifically hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and polyvinylacetate phthalate. Non-acrylates are preferred because acrylate polymers tend to become tacky and agglomerate at high temperature. Cellulose polymers are more heat stable than acrylate polymers. In addition, acrylate polymers are known to have a characteristic, slightly unpleasant taste, whereas cellulose polymers have a more neutral taste profile.

[0019] The insoluble film forming polymer may also be selected from a number of known compounds, including cellulose acetate, ethylcellulose, and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1, which is commercially available from Rohm Pharma under the tradename, "EUDRAGIT RS". One or more than one insoluble film forming polymer may be used. Preferably, the insoluble film forming polymer is impermeable and does not swell in an aqueous environment. More preferably, the insoluble film forming polymer is selected from cellulose acetate and ethylcellulose.

[0020] The weight ratio of enteric polymer to insoluble film forming polymer in the polymeric coating is preferably in the range of about 20:80 to about 80:20, more preferably about 40:60 to about 70:30.

[0021] The taste masking agent may be combined with other optional ingredients. In one embodiment, the taste masking agent is combined with one or more non-enteric, water soluble polymers, such as hydroxypropyl cellulose and poly(ethyl acrylate, methyl methacrylate, which is commercially available from Rohm Pharma GmbH under the tradename, "EUDRAGIT NE 30D." When a non-enteric, water soluble polymer is present in the polymeric coating, the level of non-enteric, water soluble polymer is preferably about 10 to about 30% of the polymeric coating.

[0022] The taste masking agent may also optionally be combined with a surfactant. Suitable surfactants include both ionic and non-ionic materials from both synthetic and natural origins, including but not limited to lecithin, glyceryl esters, sugar esters, polysorbates, mono and diglycerides of fatty acids, propylene glycol esters, sucrose fatty acid esters, polyoxyethylene derivatives of sorbitan fatty acid esters, and mixtures thereof. Examples of useful polysorbates include sorbitan trioleate, sorbitan monopalmitate, sorbitan monolaurate, propylene glycol monolaurate, glycerol monostearate, diglycerol monostearate, glycerol lactyl-palmitate, Lactic acid derivatives include sodium stearyl lactylate and calcium stearyl lactylate. When a surfactant is present in the first coating layer, the level of surfactant is present in an amount, based upon the total weight of the first coating layer, from about 2% to about 10%.

[0023] A particularly preferred first layer coating comprises about 53 wt % hydroxypropyl methylcellulose phthalate, about 43 wt % cellulose acetate, and about 4 wt % polysorbate.

[0024] The first layer coating is preferably applied to the particle core in the form of a solution using fluidized bed technology, such as Wurster coating or rotor coating. Useful solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, isopropanol; aqueous solvents such as water; and mixtures thereof. One suitable solvent mixture includes acetone and water at a ratio from about 85:15 to about 95:5.

[0025] The thickness of the first layer coating on the core is typically from about 1 micron to about 20 microns, e.g. from about 2 microns to about 15 microns or from about 4 to about 9 microns. The first layer coating may be present in an amount, based upon the total weight of the taste masked particle before the addition of the texture masking overcoating thereto, from about 5 percent to about 50 percent, e.g. from about 15 percent to about 25 percent.

[0026] The first layer coating is then overcoated with a texture masking coating layer comprised of a water soluble and/or water swellable film forming polymer and an anti-grit agent. Examples of suitable film forming polymers include, but are not limited to, all pharmaceutically suitable water soluble cellulosic polymers that nonexclusively include hydroxypropyl methylcellulose ("HPMC"), hydroxypropyl cellulose ("HPC"), hydroxyethyl cellulose ("HEC"), and sodium carboxy methyl cellulose ("sodium CMC"); starches; alginates; polyvinyl alcohols; xanthan gums; guar gums; polysaccharides; pectins; gelatins; and mixtures thereof with HPMC being preferred. Examples of suitable anti-grit agents include, but are not limited to polyethylene glycol ("PEG"), polyethylene oxide ("PEO"), mineral oils, waxes, silicone derivatives, and mixtures thereof, with PEG and PEO being preferred, and PEG being particularly preferred.

[0027] The weight ratio of film-forming polymer to anti-grit agent in the texture masking layer overcoating may be in the range of about 10:90 to about 90:10, e.g. about 20:80 to about 80:20, about 60:40 to about 40:60, or about 50:50

to about 50:50.

[0028] In one embodiment, the texture masking overcoating layer is comprised of about 50 wt % HPMC and about 50 wt % PEG. A particularly preferred HPMC is substitution type 2910 (USP) or 2208 (USP), and has a viscosity of about 6 centipoise in a 2% aqueous solution. A particularly preferred PEG has a molecular weight of about 8000 daltons.

[0029] Any of the optional ingredients set forth above for use in the first layer may be used in the same amounts in the texture masking overcoating layer.

[0030] The thickness of the texture masking overcoating on the coated core is typically from about 1 to about 20 microns, e.g., from about 2 to about 15 microns or from about 4 microns to about 9 microns. The texture masking overcoating is present in an amount, based upon the weight of the taste masked particle, from about 2 percent to about 40 percent, e.g. from about 3 percent to about 20 percent or about 5 percent to about 10 percent.

[0031] The texture masking overcoating may be applied to the coated core via any of the methods set forth above for coating the core with the first taste masking layer. A preferred method for applying the texture masking overcoating is to dissolve the film forming polymer and anti-grit agent in a suitable solvent, then apply the coating solution to the particle core, which is either coated with a taste masking layer or is uncoated, using fluidized bed technology such as Wurster coating or rotor coating. Useful solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, isopropanol; aqueous solvents such as water; and mixtures thereof. A preferred solvent mixture is ethanol and water. In this embodiment the ratio of ethanol to water in the coating solution is typically from about 10:90 to about 90:10, e.g. from about 50:50 to about 80:20. One skilled in the art may readily appreciate that the coating conditions, such as solution spray rate, drying air temperature and flow rate must be adjusted in order to achieve an equilibrium between the rate of application of the liquid coating solution, and the rate of evaporation of the solvents such that the texture masking coating can be deposited uniformly on the particle to form a complete film without overwetting the particle surface. Details of these methods are well known in the art and set forth in, for example, Lieberman et al., "Pharmaceutical Dosage Forms - Tablets: Volume 3", Chapter 3: Particle Coating Methods (1990), which is incorporated by reference herein.

[0032] In another embodiment, the uncoated core layer, i.e. the core layer without a tastemasking coating layer, may be substantially covered with the texture masking overcoating. Any of the optional ingredients set forth above for use in the first layer may be added in the same amounts to the texture masking overcoating. In this embodiment, the texture masking overcoating may be present in an amount, based upon the total weight of core and texture masking overcoating, from about 2 percent to about 40 percent, e.g. from about 3 percent to about 20 weight percent. The texture masking overcoating may be applied to the uncoated core via any of the methods set forth above for applying the tastemasking coating to the core.

[0033] In yet another embodiment, the texture masked particle may be manufactured by spray-drying whereby in general the active ingredient is suspended or dissolved, along with the film forming polymer and anti-grit agent and optional other ingredients, in a suitable solvent. Suitable solvents include any of the pharmaceutically suitable organic solvents such as acetone, methanol, ethanol, isopropanol; aqueous solvents such as water; and mixtures thereof. The solution or suspension is then sprayed into a hot drying air stream, resulting in evaporation of the solvent. One skilled in the art may readily appreciate that the spray-drying conditions, such as dryer configuration, spray rate, atomization conditions, drying air temperature and flow rate must be adjusted in order to achieve optimum particle size and morphology. Details of these methods are well known in the art and set forth in, for example, Masters, "Spray Drying Handbook, (1979), which is incorporated by reference herein.

[0034] In the embodiment wherein the texture masked particle is produced via spray-drying, the texture masked particle comprises a matrix of active ingredient, film forming polymer, and anti-grit agent such that all of these components may be present at the surface of the particle. The particle will be texture-masked by the presence of the film forming polymer and anti-grit agent at the particle surface in an amount effective for texture masking the active ingredient. The texture masked particles of this embodiment will range in average diameter from about 50 to about 500 microns; e.g. from about 80 to about 400 microns. The weight ratio of film-forming polymer to anti-grit agent in the spray-dried texture masked particle may be in the range of about 10:90 to about 90:10, e.g. about 20:80 to about 80:20, about 60:40 to about 40:60, or about 50:50 to about 50:50. The film forming polymer and the anti-grit agent together are present in an amount, based on the weight of the texture masked spray-dried particle, from about 25 to about 90%, e.g. about 40 to about 80%, or about 50 to about 75%.

[0035] Optional ingredients suitable for use in the spray-dried, texture-masked particles include but are not limited to fillers, including water soluble compressible carbohydrates such as sucrose, mannitol, sorbitol, maltitol, xylitol, erythritol, lactose, and mixtures thereof; conventional dry binders including cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, maltodextrin, and mixtures thereof, and in particular microcrystalline cellulose, maltodextrin, and starch; sweeteners including aspartame, acesulfame potassium, sucralose and saccharin; disintegrants such as microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose; preservatives, flavors, acidulants, antioxidants, glidants, surfactants, and coloring agents.

[0036] Tablets comprised of the particles of the present invention may be made by any means known in the art. More

specifically, these tablets may be comprised of a mixture of the taste masked and texture masked particles, the texture masked particles, or combinations of the same, along with common tablet excipients known in the art.

[0037] Conventional methods for tablet production include direct compression ("dry blending"), dry granulation followed by compression, and wet granulation followed by drying and compression. Other methods include the use of compacting roller technology such as a chilsonator or drop roller, or molding, casting, or extrusion technologies. All of these methods are well known in the art, and are described in detail in, for example, Lachman, et al., "The Theory and Practice of Industrial Pharmacy," Chapter 11, (3rd Ed. 1986), which is incorporated by reference herein. Preferably the tablets may be formed by the direct compression method, which involves directly compacting a blend of the taste masked and texture masked particles, the texture masked particles, or combinations of the same, and any other appropriate optional ingredients. After blending, a pre-determined volume of particles is filled into a die cavity of a rotary tablet press, which continuously rotates as part of a "die table" from the filling position to a compaction position. The particles are compacted between an upper punch and a lower punch to an ejection position, at which the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary "take-off bar."

[0038] In embodiments wherein a chewable tablet is desired, the degree of particle compaction is controlled so that the resulting tablets are relatively soft, i.e. they have a hardness of up to about 15 kiloponds per square centimeter (kp/cm²), e.g. from about 1 kp/cm² to about 10 kp/cm² or from about 2 kp/cm² to about 6 kp/cm². "Hardness" is a term used in the art to describe the diametrical breaking strength as measured by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength is normalized for the area of the break (which may be approximated as the tablet diameter times the thickness). This normalized value, expressed in kp/cm², is sometimes referred in the art as tablet tensile strength. A general discussion of tablet hardness testing is found in Lieberman et al., *Pharmaceutical Dosage Forms - Tablets*, Volume 2, 2nd ed., Marcel Dekker Inc., 1990, pp. 213 - 217, 327 - 329 (hereinafter "Lieberman").

[0039] The active ingredient is present in the chewable tablet in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dose regime, the age and weight of the patient, and other factors must be considered.

[0040] The chewable tablet may contain other conventional ingredients such as fillers, including water soluble compressible carbohydrates such as sucrose, mannitol, sorbitol, maltitol, xylitol, erythritol, lactose, and mixtures thereof; conventional dry binders including cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, modified starch, and mixtures thereof, and in particular microcrystalline cellulose; sweeteners including aspartame, acesulfame potassium, sucralose and saccharin; disintegrants such as microcrystalline cellulose, starch, sodium starch glycolate; crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose; and lubricants, such as magnesium stearate, stearic acid, talc, and waxes. The chewable tablet may also incorporate pharmaceutically acceptable adjuvants, including for example preservatives, flavors, acidulants, antioxidants, glidants, surfactants, and coloring agents.

[0041] Texture masked particles produced in accordance with the present invention advantageously may be used for immediate release applications because the texture masking coating does not retard the dissolution of the active ingredient. Preferably the texture masked particles meet the USP dissolution specifications for the specific active ingredient they contain. In a preferred embodiment for the active ingredient acetaminophen, at least about 70% of the active ingredient is released in 45 minutes from particles tested using USP Dissolution Apparatus II (paddle method) in pH 5.8 phosphate buffer at 75 rpm. In a preferred embodiment for the active ingredient ibuprofen, at least about 70% of the active ingredient is released in 30 minutes from particles tested using USP dissolution apparatus II (paddle method) in pH 7.2 phosphate buffer at 150 rpm.

[0042] Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples, but rather to the scope of the appended claims. Unless otherwise stated, the percentages and ratios given below are by weight.

Examples

Example 1. Preparation of comparative chewable tablets

[0043] The following ingredients set forth below in Table A were placed in a plastic bag and blended via inverting the bag 100 times:

Table A:

Components of Chewable Particles	
Component Name	Amount Used (mg/tablet)
Ethylcellulose encapsulated acetaminophen*	274.7
Aspartame ***	11.55
Acesulfame Potassium**	5.78
Citric acid****	2.00
Granular mannitol****	500
Fumaric acid****	20
Microcrystalline cellulose***	77
Orange flavor****	2

* comprising, based upon total component weight, a 94.5% acetaminophen core surrounded by a 5.5% ethylcellulose coating layer and available from Eurand America;

** available from Hoechst, GmbH under the tradename, "SUNETT;"

*** available from FMC Corporation under the tradename, "AVICEL PH101;"

****These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

[0044] After adding 5.78 mg of magnesium stearate thereto, the resulting mixture was further blended by inverting the bag for an additional 20 times.

[0045] The resulting blend was then removed from the bag and compressed on a rotary tablet press at 40 rpm using 19/32" diameter flat faced beveled edge tablet tooling in order to yield tablets having a weight of 898.8 mg, a hardness of 3.1 kp as determined by the Hardness test set forth in Lieberman, and a thickness of 0.19 inches.

Example 2: Preparation of Texture-Masked Particles

A. Preparation of Texture-Masking Coating Solution:

[0046] A texture masking coating solution was prepared by dispersing equal amount of hydroxypropylmethyl cellulose and polyethylene glycol 800 together with acesulfame potassium (1% of solids) in a solvent comprising 77% ethanol and 23% water so that the solid materials represented 10% of the finished solution. The components of the finished solution are set forth in Table B below:

Table B:

Texture Masking coating Solution Composition	
Component Name	Amount Used (g)
Ethanol***	604.72
Purified water	177.89
Hydroxypropylmethyl cellulose*	43.05
Polyethylene glycol 8000***	43.05
Acesulfame potassium**	0.87
Total	869.58

* available from Shin Etsu under the tradename, "PHARMACOAT 606;"

** available from Hoechst, GmbH under the tradename, "SUNETT;"

***These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

B. Coating the Active Ingredient with Texture Masking Solution

[0047] 1000 g of the encapsulated acetaminophen starting material from Example 1 were charged into a rotary fluid bed coater (Glatt GPCG-5). The powder bed was mobilized using a rotor speed of 300 rpm and air volume of 0.65 inches of water. The texture masking coating solution was sprayed onto the particles through tangentially oriented nozzles at a rate of 30 g per minute. Inlet air temperature was 50°C. After all of the solution was sprayed, the resulting texture masked coated particles were dried at a decreased rotor speed of 100 rpm for 5 minutes. The final dried batch weighed 1061 g (97% yield). The level of the texture masking coating materials was 7% by weight of the total finished texture masked and taste masked coated particles. The resulting coated particles had an average diameter of 380 microns with a standard deviation of 70 microns according to a normal distribution model ($r^2=0.984$). 73.8% of the particles had an average diameter between 300 and 425 microns.

Example 3. Preparation of chewable tablets

[0048] Coated particles from Example 2 (7% texture masking overcoating level of HPMC/FEG 8000 on ethylcellulose-coated acetaminophen) were blended with aspartame, acesulfame potassium, citric acid, granular mannitol, fumaric acid, microcrystalline cellulose, and flavor in a plastic bag by inverting 100 times. Magnesium stearate was added, and the mixture was further blended by inverting 20 times. The components of the resulting blend are set forth in Table C below:

Table C:

Components of Chewable Blend	
Component Name	Amount Used (mg / tablet)
Encapsulated and overcoated acetaminophen (87.9% active)*	290.7
Aspartame***	11.55
Acesulfame Potassium**	5.78
Citric Acid ***	2.00
Mannitol ***	500
Microcrystalline cellulose ****	77
Fumaric Acid NF***	20
Orange flavor***	2
Magnesium stearate***	5.78
TOTAL	914.81

* Prepared in Example 2;

** available from Hoechst, GmbH under the tradename, "SUNETT"

*** These components are readily available and may be commercially purchased from any of the suppliers set forth in the "Handbook of Pharmaceutical Excipients (2nd Ed. 1994).

**** available from FMC Corporation under the tradename, "AVICEL PH101."

[0049] The resulting blend was compressed on a rotary tablet press at 40 rpm using 19/32" diameter flat faced beveled edge tablet tooling to yield tablets having an average tablet weight of 914.8 mg, a tablet hardness of 3.1 kp as determined by the Hardness test in Lieberman, and a tablet thickness of 0.2 inches. Friability by USP method was 3.3%.

Example 4: Evaluation of chewable tablets from Examples 1 and 3

[0050] The tablets prepared in Examples 1 and 3, respectively, were independently sampled by panelists, who evaluated each respective tablet on the basis of taste, texture, and dissolution.

[0051] Both tablets were found to have had a similar taste, with a very slight bitterness detected by most panelists. The tablets from Example 1 were found to have had a perceptible grittiness, which ranged from "slight" to "obvious," and a rough surface. By contrast, the "texture-masked" particles of the present invention produced in accordance with Example 3 were found to have had no grittiness, a smooth texture and a "good melt-away," i.e. the tablet was rapidly cleared from the oral cavity with minimal chewing required.

[0052] The tablets from Example 1 and Example 3 were also evaluated for dissolution by USP paddle method (Apparatus II) in a pH 5.8 phosphate buffer at 75 rpm. 100% of the acetaminophen active ingredient was released from the tablets of Example 1 and Example 3 in 45 minutes.

[0053] This Example showed that although the texture masked overcoated tablets of the present invention had a flavor similar to that of the prior art tablets, the former were smoother and less gritty. As a result, the texture masked overcoated tablets are more suited for chewable tablet form.

Claims

1. A texture masked particle comprising:

- a) a core containing an active ingredient; and
- b) a texture masking coating layer on the surface of the core, the texture masking coating layer being comprised of

- i) a film forming polymer; and
- ii) an anti-grit agent.

2. A texture masked particle comprising:

- a) a core containing an active ingredient;
- b) a first layer comprised of a taste masking agent that substantially covers the core; and
- c) a second coating layer on the a surface of the first coating layer, the second coating layer being comprised of

- i) a film forming polymer; and
- ii) an anti-grit agent.

3. The particle of claim 1 or claim 2, wherein the second coating layer substantially covers the first coating layer.

4. The particle of claim 1 or claim 2, wherein the active ingredient is selected from the group consisting of a nonsteroidal anti-inflammatory drug, acetaminophen, pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, dimenhydrinate, meclizine, famotidine, joperamide, ranitidine, cimetidine, astemizole, loratadine, desloratadine, fexofenadine, cetirizine, antacids, pharmaceutically acceptable salts thereof, metabolites thereof, and mixtures thereof.

5. The particle of claim 2, wherein the taste masking agent is comprised of a mixture of a) an enteric polymer; and b) an insoluble film forming polymer.

6. The particle of claim 5, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and mixtures thereof.

7. The particle of claim 5, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, and mixtures thereof.

8. The particle of claim 5, wherein the weight ratio of enteric polymer to insoluble film forming polymer in the first coating layer is in the range of 20:80 to 80:20.

9. The particle of claim 1 or claim 2 which meets the USP dissolution specification for immediate release dosage forms containing the particular active ingredient.

10. The particle of claim 1 or claim 2 wherein the film forming polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and sodium carboxy methyl cellulose, starches, alginates, polyvinyl alcohols, xanthan gums, guar gums, polysaccharides, pectins, gelatins, and mixtures thereof.

11. The particle of claim 1 or claim 2 wherein the anti-grit agent is selected from the group consisting of polyethylene

oxide, polyethylene glycol, and mixtures thereof.

12. The particle of claim 1 or claim 2 wherein the weight ratio of film forming polymer to anti-grit agent in the second coating layer is in the range of about 50:50.

13. A tablet comprised of the particles of any one of claims 1 to 12.

14. A method of texture masking particles comprising an active ingredient, which comprises:

- a) applying a substantially continuous first coating layer over the particles, the first coating layer comprising a taste masking agent; and
- b) applying a second coating layer on the surface of the first coating layer, the second coating layer comprising a mixture of 1) a film forming polymer; and 2) an anti-grit agent.

15. A method of texture masking particles comprising an active ingredient, which comprises:

- a) applying a coating layer over the active ingredient, the coating layer comprising a mixture of 1) a film forming polymer; and 2) an anti-grit agent.

16. A texture masked particle comprising a matrix is comprised of:

- a) an active ingredient
- b) a film forming polymer, and
- c) an anti-grit agent,

wherein the film forming polymer and anti-grit agent are exposed at the surface of the particle in an amount effective for texture masking the active ingredient.

17. A method for making texture masked particles comprising an active ingredient, the method comprising spray-drying a mixture comprising:

- a) a film forming polymer and an anti-grit agent, which together are present in an amount effective for texture masking the active ingredient; and
- b) the active ingredient.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 31 0751

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	EP 0 458 751 A (WARNER LAMBERT CO) 27 November 1991 (1991-11-27) * abstract * * page 3, line 33 - line 45 * * page 4, line 42 - line 54 * * page 5, line 27 - line 57 *	1-3, 5-10, 13-17	A61K9/00 A61K9/14 A61K9/16 A61K9/28
X	WO 88 06893 A (BENZON PHARMA AS) 22 September 1988 (1988-09-22) * abstract * * page 7, line 15 - line 28 * * page 10, line 25-27 * * examples 2,3 *	1,10-17	
X	US 5 455 047 A (BEQUETTE ROBERT J ET AL) 3 October 1995 (1995-10-03) * abstract * * column 2, line 47 - column 3, line 2 * * column 6, line 32 - line 37 *	1,11-13, 15-17	
X	US 4 675 236 A (OHKAWARA MASAOKI ET AL) 23 June 1987 (1987-06-23) * column 3, line 55 - column 4, line 22 * * column 4, line 59 - line 63 *	1,10,13, 15-17	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
X	US 5 681 382 A (KOKUBO HIROYASU) 28 October 1997 (1997-10-28) * column 3, line 46 - line 49 * * column 4, line 31 - line 51 * * examples *	1,9-11, 13,15-17	
X	EP 0 608 850 A (RECORDATI CHEM PHARM) 3 August 1994 (1994-08-03) * page 4, line 18 - line 57 * * page 7, line 37 - line 41 * * examples 5,6 *	1-17	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 10 May 2002	Examiner Villa Riva, A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (PO/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 31 0751

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-05-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0458751	A	27-11-1991	EP	0458751 A1	27-11-1991
			JP	4270216 A	25-09-1992
WO 8806893	A	22-09-1988	AU	605859 B2	24-01-1991
			AU	1546088 A	10-10-1988
			CA	1312280 A1	05-01-1993
			DK	633288 A	11-11-1988
			WO	8806893 A1	22-09-1988
			EP	0308452 A1	29-03-1989
			FI	885122 A	07-11-1988
			JP	1502668 T	14-09-1989
			NO	885069 A	14-11-1988
			US	5147655 A	15-09-1992
			US	5288500 A	22-02-1994
US 5455047	A	03-10-1995	US	5372823 A	13-12-1994
			US	4956182 A	11-09-1990
			AT	128031 T	15-10-1995
			AU	617601 B2	28-11-1991
			AU	5136790 A	20-09-1990
			BG	60501 B1	30-06-1995
			CA	2012300 A1	16-09-1990
			CN	1045921 A , B	10-10-1990
			CS	277488 B6	17-03-1993
			DD	292837 A5	14-08-1991
			DE	69022452 D1	26-10-1995
			DE	69022452 T2	14-03-1996
			DK	387885 T3	06-11-1995
			EG	19669 A	30-08-1995
			EP	0387885 A2	19-09-1990
			ES	2078917 T3	01-01-1996
			FI	92464 B	15-08-1994
			GR	3017460 T3	31-12-1995
			HK	51396 A	29-03-1996
			HU	54489 A2	28-03-1991
			IE	70591 B1	11-12-1996
			JP	2974719 B2	10-11-1999
			JP	3236326 A	22-10-1991
			KR	140211 B1	01-06-1998
			NO	176043 B	17-10-1994
			NZ	232864 A	28-04-1992
			OA	9198 A	30-06-1992
			PL	163301 B1	31-03-1994
			PT	93452 A , B	07-11-1990
			RO	106953 B1	30-08-1993
			RU	2069558 C1	27-11-1996

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 31 0751

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-05-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5455047	A		YU 52390 A1	31-10-1991
			ZA 9002001 A	28-11-1990
			ZW 1890 A1	31-10-1990
US 4675236	A	23-06-1987	JP 1795811 C	28-10-1993
			JP 4075054 B	27-11-1992
			JP 61174940 A	06-08-1986
			EP 0234078 A1	02-09-1987
US 5681382	A	28-10-1997	JP 9059146 A	04-03-1997
			JP 9059147 A	04-03-1997
EP 0608850	A	03-08-1994	IT 1264020 B	09-09-1996
			AT 169497 T	15-08-1998
			DE 69412295 D1	17-09-1998
			DE 69412295 T2	11-02-1999
			DK 608850 T3	17-05-1999
			EP 0608850 A1	03-08-1994
			ES 2122050 T3	16-12-1998
			JP 3184912 B2	09-07-2001
			JP 6319786 A	22-11-1994
			SG 47772 A1	17-04-1998
			US 5460828 A	24-10-1995